

Study explores dose ranges for efpeglenatide in early T2DM

August 5 2019



(HealthDay)—Efpeglenatide once weekly leads to dose-dependent

reductions in glucose and body weight in patients with early type 2 diabetes, according to a phase 2 study published online July 18 in *Diabetes Care*.

Julio Rosenstock, M.D., from the Dallas Diabetes Research Center at Medical City, and colleagues evaluated the safety and efficacy of once-weekly efpeglenatide, a long-acting glucagon-like peptide 1 receptor agonist (GLP-1 RA), in early type 2 diabetes (drug naive or on metformin monotherapy [90 percent]). Among the participants, 181 were randomly assigned to one of five efpeglenatide doses (0.3, 1, 2, 3, or 4 mg q.w.), 37 received a [placebo](#), and 36 received liraglutide (≤ 1.8 mg daily).

The researchers found that during the 12-week study period, all efpeglenatide doses ≥ 1 mg significantly reduced HbA1c versus placebo to a final HbA1c of 6.3 to 6.8 percent versus 7.7 to 8 percent at baseline. Masked efpeglenatide 4 mg was noninferior to open-label liraglutide. Compared with placebo, greater proportions treated with efpeglenatide ≥ 1 mg achieved HbA1c

Citation: Study explores dose ranges for efpeglenatide in early T2DM (2019, August 5) retrieved 24 April 2024 from

<https://medicalxpress.com/news/2019-08-explores-dose-ranges-efpeglenatide-early.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--